AGP Executive Report
Last update: 9 hours agoCross-Border Care in Europe: A new explainer breaks down when patients can get treatment abroad, what costs may be covered, when prior authorisation is needed, and how to claim—especially relevant for planned care, urgent needs while travelling, and prescriptions filled across borders. Rett Syndrome Drug Progress: Neuren’s DAYBU (trofinetide) cleared a major step in Europe after a positive CHMP opinion following re-examination, moving to a European Commission decision; if approved, it would be the first EU option for neurobehavioral symptoms of Rett syndrome. Cancer Treatment Updates (Bladder & Breast): The European Commission approved KEYTRUDA plus Padcev for cisplatin-ineligible muscle-invasive bladder cancer in a perioperative plan, and also authorised Trodelvy for first-line metastatic triple-negative breast cancer for patients not suitable for PD-(L)1 inhibitors. Travel & Disability Practicalities: Guidance highlights that Blue Badge holders may have reciprocal parking access in Liechtenstein and other countries. Public Health & Safety: A global map shows where safe drinking water is still out of reach, underscoring ongoing infrastructure gaps that affect health.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
